Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant HPV Type 6/11 Bivalent Vaccine in Healthy Volunteers
NCT02710851Phase 2Unknown
- Start
- Mar 2016
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of recombinant human papillomavirus type 6/11 bivalent vaccine in condylomata acuminata (4 arms). Primary endpoints: Anti-HPV 6 and anti-HPV 11 seroconversion rates at 7 months and Anti-HPV 6 and anti-HPV 11 geometric mean concentrations at 7 months. Status: unknown.
02
Drugs
recombinant human papillomavirus type 6/11 bivalent vaccine
03
Conditions
condylomata acuminata
Beyond the preview
Go deeper on NCT02710851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02710851.